{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T11:39:49Z","timestamp":1787744389582,"version":"build-2784847793"},"reference-count":51,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,7]],"date-time":"2021-10-07T00:00:00Z","timestamp":1633564800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006692","name":"Universit\u00e0 degli Studi di Torino","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006692","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","award":["634413"],"award-info":[{"award-number":["634413"]}],"id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007076","name":"Airc Italian Foundation for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007076","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002803","name":"Fondazione Cariplo","doi-asserted-by":"publisher","award":["2011-0470"],"award-info":[{"award-number":["2011-0470"]}],"id":[{"id":"10.13039\/501100002803","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["15274"],"award-info":[{"award-number":["15274"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003500","name":"Universit\u00e0 degli Studi di Padova","doi-asserted-by":"publisher","award":["CPDA110795"],"award-info":[{"award-number":["CPDA110795"]}],"id":[{"id":"10.13039\/501100003500","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cmghjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cellular and Molecular Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2022]]},"DOI":"10.1016\/j.jcmgh.2021.10.002","type":"journal-article","created":{"date-parts":[[2021,10,14]],"date-time":"2021-10-14T06:45:37Z","timestamp":1634193937000},"page":"459-482","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Hepatocyte-Specific Deletion of HIF2\u03b1 Prevents NASH-Related Liver Carcinogenesis by Decreasing Cancer Cell Proliferation"],"prefix":"10.1016","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7973-9681","authenticated-orcid":false,"given":"Beatrice","family":"Foglia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Sutti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Cannito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Rosso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Maggiora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Autelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Novo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Bocca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianmarco","family":"Villano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naresh Naik","family":"Ramavath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramy","family":"Younes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignazia","family":"Tusa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Rovida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"Pontisso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Bugianesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Albano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Parola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcmgh.2021.10.002_bib1","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1002\/hep.30251","article-title":"Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis","volume":"69","author":"Younossi","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.jcmgh.2021.10.002_bib2","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.jhep.2014.11.034","article-title":"Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management","volume":"62","author":"McPherson","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jcmgh.2021.10.002_bib3","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","article-title":"The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"71","author":"Younossi","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jcmgh.2021.10.002_bib4","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1055\/s-0032-1306424","article-title":"Nonalcoholic steatohepatitis and noncirrhotic hepatocellular carcinoma: fertile soil","volume":"32","author":"Torres","year":"2012","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jcmgh.2021.10.002_bib5","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.jhep.2017.10.006","article-title":"Should we undertake surveillance for HCC in patients with NAFLD?","volume":"68","author":"Younes","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jcmgh.2021.10.002_bib6","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.cgh.2018.05.057","article-title":"Nonalcoholic steatohepatitis is the fastest growing cause of hepatocellular carcinoma in liver transplant candidates. Global Nonalcoholic Steatohepatitis Council","volume":"17","author":"Younossi","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jcmgh.2021.10.002_bib7","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/hep.25497","article-title":"Hypoxia and hypoxia inducible factors: diverse roles in liver diseases","volume":"55","author":"Nath","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.jcmgh.2021.10.002_bib8","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.jhep.2014.08.025","article-title":"Hypoxia inducible factors in liver disease and hepatocellular carcinoma: current understanding and future directions","volume":"61","author":"Wilson","year":"2014","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jcmgh.2021.10.002_bib9","doi-asserted-by":"crossref","first-page":"3419","DOI":"10.1007\/s00018-016-2222-1","article-title":"Hypoxia-regulated mechanisms in the pathogenesis of obesity and non-alcoholic fatty liver disease","volume":"73","author":"Lefere","year":"2016","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.jcmgh.2021.10.002_bib10","doi-asserted-by":"crossref","first-page":"46691","DOI":"10.18632\/oncotarget.17358","article-title":"Hypoxia inducible factors in hepatocellular carcinoma","volume":"8","author":"Chen","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.jcmgh.2021.10.002_bib11","doi-asserted-by":"crossref","first-page":"20130676","DOI":"10.1259\/bjr.20130676","article-title":"Defining normoxia, physoxia and hypoxia in tumours-implications for treatment response","volume":"87","author":"McKeown","year":"2014","journal-title":"Br J Radiol"},{"key":"10.1016\/j.jcmgh.2021.10.002_bib12","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.molcel.2010.09.022","article-title":"Hypoxia-inducible factors and the response to hypoxic stress","volume":"40","author":"Majmundar","year":"2010","journal-title":"Mol Cell"},{"key":"10.1016\/j.jcmgh.2021.10.002_bib13","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.trecan.2016.10.016","article-title":"Hypoxia-inducible factors: master regulators of cancer progression","volume":"2","author":"Schito","year":"2016","journal-title":"Trends Cancer"},{"key":"10.1016\/j.jcmgh.2021.10.002_bib14","doi-asserted-by":"crossref","first-page":"409272","DOI":"10.1155\/2014\/409272","article-title":"The role of hypoxia inducible factor-1 in hepatocellular carcinoma","volume":"2014","author":"Luo","year":"2014","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.jcmgh.2021.10.002_bib15","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1002\/hep.23597","article-title":"Roles of hypoxia-inducible factor-1alpha (HIF-1alpha) versus HIF-2alpha in the survival of hepatocellular tumor spheroids","volume":"51","author":"Menrad","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jcmgh.2021.10.002_bib16","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1111\/j.1349-7006.2011.02177.x","article-title":"Downregulating hypoxia-inducible factor-2alpha improves the efficacy of doxorubicin in the treatment of hepatocellular carcinoma","volume":"103","author":"He","year":"2012","journal-title":"Cancer Sci"},{"key":"10.1016\/j.jcmgh.2021.10.002_bib17","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1002\/hep.26188","article-title":"Hypoxia inducible factor 2 alpha inhibits hepatocellular carcinoma growth through the transcription factor dimerization partner 3\/E2F transcription factor 1-dependent apoptotic pathway","volume":"57","author":"Sun","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jcmgh.2021.10.002_bib18","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/j.cellsig.2014.01.026","article-title":"Upregulation of HIF-2alpha induced by sorafenib contributes to the resistance by activating the TGF-alpha\/EGFR pathway in hepatocellular carcinoma cells","volume":"26","author":"Zhao","year":"2014","journal-title":"Cell Signal"},{"key":"10.1016\/j.jcmgh.2021.10.002_bib19","doi-asserted-by":"crossref","first-page":"34571","DOI":"10.18632\/oncotarget.8952","article-title":"Downregulation and pro-apoptotic effect of hypoxia-inducible factor 2 alpha in hepatocellular carcinoma","volume":"7","author":"Yang","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.jcmgh.2021.10.002_bib20","doi-asserted-by":"crossref","first-page":"10839","DOI":"10.18632\/aging.102488","article-title":"HIF-2\u03b1 upregulation mediated by hypoxia promotes NAFLD-HCC progression by activating lipid synthesis via the PI3K-AKT-mTOR pathway","volume":"11","author":"Chen","year":"2019","journal-title":"Aging"},{"key":"10.1016\/j.jcmgh.2021.10.002_bib21","doi-asserted-by":"crossref","first-page":"4527","DOI":"10.1128\/MCB.00200-09","article-title":"Hypoxia-inducible factor 2 regulates hepatic lipid metabolism","volume":"29","author":"Rankin","year":"2009","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.jcmgh.2021.10.002_bib22","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1002\/hep.24400","article-title":"Hypoxia-inducible transcription factor 2\u03b1 promotes steatohepatitis through augmenting lipid accumulation, inflammation, and fibrosis","volume":"54","author":"Qu","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jcmgh.2021.10.002_bib23","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1002\/hep.29754","article-title":"Hypoxia-inducible factor 2\u03b1 drives nonalcoholic fatty liver progression by triggering hepatocyte release of histidine-rich glycoprotein","volume":"67","author":"Morello","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jcmgh.2021.10.002_bib24","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/nature16969","article-title":"NAFLD causes selective CD4(+) T lymphocyte loss and promotes hepatocarcinogenesis","volume":"531","author":"Ma","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.jcmgh.2021.10.002_bib25","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.humpath.2011.07.005","article-title":"The steatohepatitic variant of hepatocellular carcinoma and its association with underlying steatohepatitis","volume":"43","author":"Salomao","year":"2012","journal-title":"Hum Pathol"},{"key":"10.1016\/j.jcmgh.2021.10.002_bib26","doi-asserted-by":"crossref","first-page":"E1933","DOI":"10.3390\/cancers11121933","article-title":"SerpinB3 differently up-regulates hypoxia inducible factors-1\u03b1 and -2\u03b1 in hepatocellular carcinoma: mechanisms revealing novel potential therapeutic targets","volume":"11","author":"Cannito","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jcmgh.2021.10.002_bib27","doi-asserted-by":"crossref","first-page":"4015","DOI":"10.1158\/0008-5472.CAN-10-4142","article-title":"The hypoxia-associated factor switches cells from HIF-1\u03b1- to HIF-2\u03b1-dependent signaling promoting stem cell characteristics, aggressive tumor growth and invasion","volume":"71","author":"Koh","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.jcmgh.2021.10.002_bib28","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/nrc3183","article-title":"HIF-1\u03b1 and HIF-2\u03b1: sibling rivalry in hypoxic tumour growth and progression","volume":"12","author":"Keith","year":"2011","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jcmgh.2021.10.002_bib29","doi-asserted-by":"crossref","first-page":"778","DOI":"10.3892\/ol.2015.3315","article-title":"Targeting hypoxia-inducible factor-2\u03b1 enhances sorafenib antitumor activity via \u03b2-catenin\/C-Myc-dependent pathways in hepatocellular carcinoma","volume":"10","author":"Liu","year":"2015","journal-title":"Oncol Lett"},{"key":"10.1016\/j.jcmgh.2021.10.002_bib30","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/s12276-018-0159-1","article-title":"Sorafenib resistance in hepatocarcinoma: role of hypoxia-inducible factors","volume":"50","author":"M\u00e9ndez-Blanco","year":"2018","journal-title":"Exp Mol Med"},{"key":"10.1016\/j.jcmgh.2021.10.002_bib31","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.18632\/oncotarget.2943","article-title":"Hypoxia up-regulates SERPINB3 through HIF-2\u03b1 in human liver cancer cells","volume":"6","author":"Cannito","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.jcmgh.2021.10.002_bib32","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ceb.2019.07.006","article-title":"Role of the transcriptional coactivators YAP\/TAZ in liver cancer","volume":"61","author":"Zhang","year":"2019","journal-title":"Curr Opin Cell Biol"},{"key":"10.1016\/j.jcmgh.2021.10.002_bib33","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.bbrc.2013.08.071","article-title":"Mutual interaction between YAP and c-Myc is critical for carcinogenesis in liver cancer","volume":"439","author":"Xiao","year":"2013","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.jcmgh.2021.10.002_bib34","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1053\/j.gastro.2014.05.004","article-title":"Activation of \u03b2-catenin and Yap1 in human hepatoblastoma and induction of hepatocarcinogenesis in mice","volume":"147","author":"Tao","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jcmgh.2021.10.002_bib35","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.jhep.2014.06.033","article-title":"YAP activation is an early event and a potential therapeutic target in liver cancer development","volume":"61","author":"Perra","year":"2014","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jcmgh.2021.10.002_bib36","doi-asserted-by":"crossref","first-page":"581","DOI":"10.3390\/ijms20030581","article-title":"High risk of hepatocellular carcinoma development in fibrotic liver: role of the Hippo-YAP\/TAZ signaling pathway","volume":"20","author":"Moon","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jcmgh.2021.10.002_bib37","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/s41575-020-00365-6","article-title":"Maladaptive regeneration - the reawakening of developmental pathways in NASH and fibrosis","volume":"18","author":"Zhu","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jcmgh.2021.10.002_bib38","doi-asserted-by":"crossref","first-page":"17701","DOI":"10.1038\/srep17701","article-title":"SerpinB3 and Yap interplay increases Myc oncogenic activity","volume":"5","author":"Turato","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.jcmgh.2021.10.002_bib39","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1158\/0008-5472.CAN-10-3220","article-title":"Cancer stem cell niche: the place to be","volume":"71","author":"Borovski","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.jcmgh.2021.10.002_bib40","doi-asserted-by":"crossref","first-page":"17046","DOI":"10.1074\/jbc.M117.805655","article-title":"Hypoxia-inducible factor 2\u03b1 (HIF-2\u03b1) promotes colon cancer growth by potentiating Yes-associated protein 1 (YAP1) activity","volume":"292","author":"Ma","year":"2017","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jcmgh.2021.10.002_bib41","doi-asserted-by":"crossref","first-page":"3247","DOI":"10.1002\/jcb.26481","article-title":"HIF-2\u03b1 activated lncRNA NEAT1 promotes hepatocellular carcinoma cell invasion and metastasis by affecting the epithelial-mesenchymal transition","volume":"119","author":"Zheng","year":"2018","journal-title":"J\u00a0Cell Biochem"},{"key":"10.1016\/j.jcmgh.2021.10.002_bib42","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.cell.2009.12.052","article-title":"Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression","volume":"140","author":"Park","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.jcmgh.2021.10.002_bib43","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0097136","article-title":"HCC development is associated to peripheral insulin resistance in a mouse model of NASH","volume":"9","author":"De Minicis","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jcmgh.2021.10.002_bib44","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.ccell.2014.09.003","article-title":"Metabolic activation of intrahepatic CD8+ T cells and NKT cells causes nonalcoholic steatohepatitis and liver cancer via cross-talk with hepatocytes","volume":"26","author":"Wolf","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jcmgh.2021.10.002_bib45","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.3390\/ijms20071723","article-title":"The role of fibrosis and liver-associated fibroblasts in the pathogenesis of hepatocellular carcinoma","volume":"20","author":"Baglieri","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jcmgh.2021.10.002_bib47","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1124\/mol.116.107706","article-title":"Advances in hypoxia-mediated mechanisms in hepatocellular carcinoma","volume":"92","author":"Xiong","year":"2017","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.jcmgh.2021.10.002_bib49","doi-asserted-by":"crossref","first-page":"9282","DOI":"10.1073\/pnas.1807155115","article-title":"Cyclin E1 and cyclin-dependent kinase 2 are critical for initiation, but not for progression of hepatocellular carcinoma","volume":"115","author":"Sonntag","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jcmgh.2021.10.002_bib50","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1136\/jcp.2007.051383","article-title":"Squamous cell carcinoma antigen in human liver carcinogenesis","volume":"61","author":"Guido","year":"2008","journal-title":"J\u00a0Clin Pathol"},{"key":"10.1016\/j.jcmgh.2021.10.002_bib51","doi-asserted-by":"crossref","first-page":"2708","DOI":"10.1038\/bjc.2014.246","article-title":"SERPINB3 is associated with TGF-\u03b21 and cytoplasmic \u03b2-catenin expression in hepatocellular carcinomas with poor prognosis","volume":"110","author":"Turato","year":"2014","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jcmgh.2021.10.002_bib52","doi-asserted-by":"crossref","first-page":"e8699","DOI":"10.15252\/emmm.201708699","article-title":"Cancer cell adaptation to hypoxia involves a HIF-GPRC5A-YAP axis","volume":"10","author":"Greenhough","year":"2018","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.jcmgh.2021.10.002_bib54","doi-asserted-by":"crossref","first-page":"14391","DOI":"10.1073\/pnas.0907357106","article-title":"HIF-2alpha inhibition promotes p53 pathway activity, tumor cell death, and radiation responses","volume":"106","author":"Bertout","year":"2009","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["Cellular and Molecular Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352345X21002162?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352345X21002162?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T18:30:08Z","timestamp":1762453808000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352345X21002162"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":51,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022]]}},"alternative-id":["S2352345X21002162"],"URL":"https:\/\/doi.org\/10.1016\/j.jcmgh.2021.10.002","relation":{},"ISSN":["2352-345X"],"issn-type":[{"value":"2352-345X","type":"print"}],"subject":[],"published":{"date-parts":[[2022]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hepatocyte-Specific Deletion of HIF2\u03b1 Prevents NASH-Related Liver Carcinogenesis by Decreasing Cancer Cell Proliferation","name":"articletitle","label":"Article Title"},{"value":"Cellular and Molecular Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcmgh.2021.10.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc. on behalf of the AGA Institute.","name":"copyright","label":"Copyright"}]}}